

## DAFTAR PUSTAKA

1. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. **N Engl J Med** 2000;343(25):1863-75.
2. Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire? **Nephrol Dial Transplant** 2004;19(Suppl 1):i9-i13.
3. Almaden Y, Hernandez A, Torregrosa V. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. **J Am Soc Nephrol** 1998;9:1845-52.
4. KDOQI. Clinical practice guidelines for chronic kidney disease. **Am J Kidney Dis** 2002;39:S1 -S246.
5. Gal-Moscovici A, Sprague SM. The role of calcimimetics in chronic kidney disease. **Kidney Int** 2006;70:S68 -S72.
6. De Boer IH, Gorodetskaya I, Young B, *et al.* The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. **J Am Soc Nephrol** 2002;13:2762-9.
7. McCarron DA. Protecting Calcium and Phosphate Balance in Chronic Renal Disease. **J Am Soc Nephrol** 2005;16:S93-S4.
8. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. **Am J Physiol Renal Physiol** 2005;288:F253-F64.
9. Drueke TB. Renal osteodystrophy: management of hyperphosphataemia. **Nephrol Dial Transplant** 2000;15(Suppl 5):32-3.
10. Kestenbaum B, Sampson JN, Rudser KD, *et al.* Serum phosphate levels and mortality risk among people with chronic kidney disease. **J Am Soc Nephrol** 2005;16:520-8.
11. Iwasaki Y, Yamato H, Nii-Kono T, *et al.* Insufficiency of PTH action on bone in uremia. **Kidney Int** 2006;70:S34-S6.
12. Locatelli F, Cannata-Andia JB, Drueke TB, *et al.* Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. **Nephrol Dial Transplant** 2002;17:723-31.
13. Gallieni M, Cucciniello E, D'Amaro E, *et al.* Calcium, phosphate and PTH levels in the hemodialysis population: a multicenter study. **J Nephrol** 2002;15:165-70.
14. Hruska KA, Teitelbaum SL. Renal osteodystrophy. **N Engl J Med** 1995;333(3):166-74.

15. Mesquita M, Wittersheim E, Demulder A, *et al*. Bone cytokines and renal osteodystrophy in peritoneal dialysis patients. **Adv Perit Dial** 2005;21:181-4.
16. Llach F, Fernandez E. Overview of renal bone disease: causes of treatment failure, clinical observations, the changing pattern of bone lesions, and future therapeutic approach. **Kidney Int** 2003;64(Suppl 87):s113-s9.
17. Stevens LA, Djurdjev O, Cardew S, *et al*. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. **J Am Soc Nephrol** 2004; 15:770-9.
18. Horl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. **Nephrol Dial Transplant** 2004;19(Suppl 5):v2-v8.
19. Coen G, Ballanti P, Bonucci E, *et al*. Bone markers in the diagnosis of low turnover osteodystrophy in hemodialysis patients. **Nephrol Dial Transplant** 1998;13:2294-302.
20. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. **J Clin Endocrinol Metab** 1992;75:145-50.
21. Cheng S, Coyne DW. Secondary hyperparathyroidism in the diabetic patient with chronic kidney disease. In: Business briefing: **US endocrine review**; 2005; 2005. p. 39-41.
22. Murray TM, Rao LG, Divieti P, *et al*. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminated ligands. **Endocr Rev** 2005;26:78-113.
23. Bieglmayer C, Kaczirek K, Prager G, *et al*. Parathyroid hormone monitoring during total parathyroidectomy for renal hyperparathyroidism: pilot study of the impact of renal function and assay specificity. **Clin Chem** 2006; 52(6):1112-9.
24. Reichel H, Esser A, Roth HJ, *et al*. Influence of PTH assay methodology on differential diagnosis of renal bone disease. **Nephrol Dial Transplant** 2003; 18:759-68.
25. Moe SM. Management of renal osteodystrophy in peritoneal dialysis patients. **Perit Dial Int** 2004;24:209-16.
26. Chonchol MB. Secondary hyperparathyroidism in chronic kidney disease. In; 2006: **US renal and genitourinary disease** 2006. p. 11-3.
27. Schwarz S, Trivedi BK, Kalantar-Zadeh K, *et al*. Association of disorders in mineral metabolism with progression of chronic kidney disease. **Clin J Am Soc Nephrol** 2006;1:825-31.
28. Drueke TB. Hyperparathyroidism in chronic kidney disease. In: <http://www.endotext.com>; 2006:1-30.

29. Goodman WG. Medical management of secondary hyperparathyroidism in chronic renal failure. **Nephrol Dial Transplant** 2003;18(Suppl 3):iii2-iii8.
30. Silver J. Molecular mechanisms of secondary hyperparathyroidism. **Nephrol Dial Transplant** 2000;15(Suppl 5):S2-S7.
31. Reichel H, Drueke T, Ritz E. Bony complications in chronic renal failure. In: Cameron S, Davison AM, Kerr D, eds. **Oxford Textbook of Clinical Nephrology**. Oxford: Oxford Medical Publication; 1992:1365-89.
32. Malluche HH, Monier-Faugere MC, Koszewski NJ. Use and indication of vitamin D and vitamin D analogues in patients with renal bone disease. **Nephrol Dial Transplant** 2002;17(Suppl 10):6-9.
33. Fukagawa M, Kazama JJ, Kurokawa K. Renal osteodystrophy and secondary hyperparathyroidism. **Nephrol Dial Transplant** 2002;17(Suppl 10):2-5.
34. Slatopolsky E, Finch J, Clay P. A novel mechanism for skeletal resistance in uremia. **Kidney Int** 2000;58:753-61.
35. Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, *et al*. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. **Nephrol Dial Transplant** 2005;20:1904-11.
36. Moe S, Drueke T, Cunningham J, *et al*. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). **Kidney Int** 2006;69:1945-53.
37. Coen G, Ballanti P, Balducci A, *et al*. Serum osteoprotegerin and renal osteodystrophy. **Nephrol Dial Transplant** 2002;17:233-8.
38. Gonzales EA. The role of cytokines in skeletal remodelling: possible consequences for renal osteodystrophy. **Nephrol Dial Transplant** 2000;15:945-50.
39. Olgaard K, Lewin E. Can hyperparathyroid bone disease be arrested or reversed? **Clin J Am Soc Nephrol** 2006;1:367-73.
40. Couttenye MM, D'Haese PC, Verschoren WJ, *et al*. Low bone turnover in patients with renal failure. **Kidney Int** 1999;56(Suppl 73):s70-s6.
41. Hruska K. New concepts in renal osteodystrophy. **Nephrol Dial Transplant** 1998;13:2755-60.
42. Goodman WG, Goldin J, Kuzon BD, *et al*. Coronary artery calcification in young adults with ESRD who are undergoing dialysis. **N Engl J Med** 2000; 342:1478-83.
43. Braun J, Oldendorf M, Moshage W, *et al*. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients (abstract). **Am J Kidney Dis** 1996;27:394-401.

44. Stinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS Waves 1,3,and 4 Study. **J Am Soc Nephrol** 2005;16:1788-93.
45. Drueke TB, Eckardt KU. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. **Nephrol Dial Transplant** 2002;17(5):28-31.
46. Rossert JA, Wauters JP. Recommendations for the screening and management of patients with chronic kidney disease. **Nephrol Dial Transplant** 2002;17(Suppl 1):19-28.
47. Hutchison AJ, Speake M, Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with ianthanum carbonate. **Nephrol Dial Transplant** 2004;19:1902-6.
48. Malluche HH, Mawad H. Management of hyperphosphataemia of chronic kidney disease: lessons from the past and future directions. **Nephrol Dial Transplant** 2002;17:1170-5.
49. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients **Kidney Int** 2002; 62:245-52.
50. Block GA, Spiegel DM, Ehrlich J, *et al.* Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis (abstract). **Kidney Int** 2005;68:1815-24.
51. Martinez I, Saracho R, Montenegro J, *et al.* The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. **Am J Kidney Dis** 1997;29(4):496-502.
52. De Sevaux RG, Hoitsma AJ, Corstens FHM, *et al.* Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. **J Am Soc Nephrol** 2002;13:1608 - 14.
53. Medical Expert Group. Clinical algorithms on renal osteodystrophy. **Nephrol Dial Transplant**;15(Suppl 5):40-57.
54. Situmorang TD. Terapi pengganti ginjal pada gagal ginjal kronik. In: **Kursus Nefrologi Klinik Kongres Nasional VIII PERNEFRI**; 2002; Surabaya; 2002.
55. Avram M, Mittman N, Mying M, *et al.* Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation (abstract). **Am J Kidney Dis** 2001;38:1351-7.
56. Guh JY, Chen HC, Chuang HY, *et al.* Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients (abstract). **Am J Kidney Dis** 2002;39:1245-54.
57. Ganesh SK, Stack AG, Levin NW, *et al.* Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. **J Am Soc Nephrol** 2001;12:2131-8.

58. Gipstein RM, Coburn JW, Adams DA. Calciphylaxis in man (abstract). **Arch Intern Med** 1976;136:1273-80.
59. Lubis HR. Penanganan nefropati diabetik. In: **JNHC**; Jakarta; 2003. p. 11-7.
60. Nowicki M, Kokot F, Surdacki A. The influence of hyperinsulinaemia on calcium-phosphate metabolism in renal failure. **Nephrol Dial Transplant** 1998;13:2566-71.
61. Nowicki M, Fliser D, Fode P, *et al.* Change in plasma phosphate levels influence insulin sensitivity under euglycemic conditions (abstract). **J Clin Endocrinol Metab** 1996;81:156-9.
62. Gupta A, Kallenbach LR, Zasuwa G, *et al.* Race is a major determinant of hyperparathyroidism in uremic patients. **J Am Soc Nephrol** 2000; 11:330-4.
63. Block GA, Port FK. A re-evaluation of the risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management (abstract). **Am J Kidney Dis** 2000;35:1-14.
64. Gerakis A, Hutchison AJ, Apostolou TH, *et al.* Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. **Nephrol Dial Transplant** 1996;11:2430-8.
65. Monier-Faugere MC, Geng Z, Mawad H. Improved assessment of bone turnover by the PTH(1-84)/large CPTH fragments ration in ESRD patients. **Kidney Int** 2001;60:1460-8.
66. Salem MM. Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. **Am J Kidney Dis** 1997;29:862-5.
67. Murer H, Hernando N, Forster I, *et al.* Proximal tubular phosphate reabsorption: molecular mechanisms. **Physiol Rev** 2000;268:F784-F91.
68. Shigematsu T, Kono T, Satoh K, *et al.* Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients. **Nephrol Dial Transplant** 2003;18(Suppl 3):iii86-iii9.
69. Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients (abstract). **Nephrol Dial Transplant** 1996;11(Suppl 3):111-20.
70. DeFronzo RA, Alvestrand A, Smith D. Insulin resistance in uremia. **J Clin Invest** 1981;67:563-8.

*Lampiran 1.*

**FORMULIR PERSETUJUAN BERPARTISIPASI DALAM PENELITIAN**

**SURAT PERNYATAAN**

Setelah mendapatkan penjelasan mengenai maksud, tujuan serta manfaat penelitian dengan judul **HIPERPARATIROIDISME SEKUNDER PADA PENDERITA PENYAKIT GINJAL KRONIK TAHAP AKHIR : Hubungannya Dengan Lama Hemodialis, Kadar Kalsium Dan Fosfat Serta Adanya Diabetes Mellitus**, maka saya yang bertanda-tangan di bawah ini:

Nama :  
Umur :  
Alamat :

Menyetujui dan bersedia diikutsertakan dalam penelitian ini.

Dan bila suatu waktu merasa dirugikan dalam bentuk apapun, saya berhak menghentikan peran serta saya dalam penelitian ini kapan saja dengan cara memberitahukan kepada peneliti.

Demikianlah pernyataan persetujuan ini saya buat dalam keadaan sadar dan tanpa paksaan dari pihak manapun.

Makassar, .....

Peneliti

Saksi

Peserta penelitian

(dr. Nella Suhyanly)

(

) (

)

Lampiran 2.

## FORMULIR PENELITIAN

### HIPERPARATIROIDISME SEKUNDER PADA PENDERITA PENYAKIT GINJAL KRONIK TAHAP AKHIR : Hubungannya Dengan Lama Hemodialisis, Kadar Kalsium Dan Fosfat Serta Adanya Diabetes Mellitus,

#### I. IDENTITAS

- ? Nama : .....
- ? Rumah sakit : ..... RM: .....
- ? Tanggal : .....
- ? Alamat : .....
- ? Telpn : .....
- ? Umur : ..... Jenis kelamin : .....

#### II. DATA UMUM

- ? Tekanan darah : ..... mmHg
- ? Tinggi badan : ..... cm
- ? Berat badan : ..... kg
- ? Ureum : ..... mg/dL
- ? Kreatinin : ..... mg/dL

#### III. DATA KLINIS

- ? Keadaan umum : 1. Baik      2. Sedang      3. Lemah
- ? Penyebab PGK : .....
- ? Lama HD : ..... bulan
- ? Riwayat DM : ..... bulan
- ? Riw. terapi :
- |                |    |       |
|----------------|----|-------|
| Kalsium        | Ya | Tidak |
| Vitamin D      | Ya | Tidak |
| Steroid /OAINS | Ya | Tidak |